On March 15, there was some big news for one of Bio-Thera's major pipeline products. The phase I clinical trial for BAT1706
(a bevacizumab biosimilar), which is currently carrying out its global
development plan, has enrolled its first two healthy subjects in New
Zealand. This is the first clinical study of a bevacizumab biosimilar to
be conducted overseas by a Chinese company. At present, the clinical
study is proceeding as planned, with the phase I final report expected
to be completed in February 2017.
The
CEO of Bio-Thera, Dr. Li Shengfeng, believes that BAT1706 is leading
the way for Bio-Thera's many other outstanding products to begin their
own international clinical testing, and in the next few years we will be
launching global clinical trials for over a dozen other biosimilar
drugs. This will lay the foundation for Bio-Thera to achieve its goal of
becoming the first global biopharmaceutical company in Guangzhou to
launch "Proudly Made In China" products.
